FDA

Gilead’s Yeztugo® Becomes First FDA-Approved Twice-Yearly Injectable for HIV Prevention

Policy & Public Health

Gilead’s Yeztugo® Becomes First FDA-Approved Twice-Yearly Injectable for HIV Prevention

20 Jun 2025

2 min read

Bayer Submits New Drug Application to FDA for Gadoquatrane, a Low-Dose MRI Contrast Agent

Bayer Submits New Drug Application to FDA for Gadoquatrane, a Low-Dose MRI Contrast Agent

17 Jun 2025

2 min read

FDA Approves Pembrolizumab for Perioperative Use in Head and Neck Cancer, Marking First Approval in Six Years

Precision Medicine

FDA Approves Pembrolizumab for Perioperative Use in Head and Neck Cancer, Marking First Approval in Six Years

14 Jun 2025

2 min read

Read More

Voice Of HealthCare

vohnetwork.com